Table 2.

Ongoing Clinical Trials Featuring NK Cell Therapy in Gastric Cancer Patients.

Clinical Trial Information	NK Cell Type	Other Therapy	Patient Population	Status
NCT03319459 Phase I	Fate-NK100 (allogeneic NK cell subset expressing the maturation marker CD57)	N/A	Various solid tumors	Completed, awaiting results
NCT05069935 Phase I	FT538 NK cells derived from an induced pluripotent stem cells with modifications to enhance ADCC and persistence	All receive cyclophosphamide and fludarabine prior to NK cells. Plus: Avelumab in FDA-approved tumors, Trastuzumab in HER2+	Various solid tumors	Recruiting
NCT04319757 Phase I	ACE1702: anti-HER2 antibody-cell conjugate, off-the-shelf NK cell product	Cyclophosphamide and fludarabine prior to NK cells.	Advanced or metastatic HER2+ tumors	Recruiting
NCT04385641	Umbilical cord blood derived NK cells	Cyclophosphamide and fludarabine prior to NK cells.	Advanced GC or GEJC	Recruiting
NCT04847466 Phase II	Irradiated PD-L1 CAR-NK Cells	Pembrolizumab and N-803 (IL15 super-agonist)	Recurrent or metastatic GC or head/neck cancer	Recruiting
NCT05207722 Phase I/IIa	CYNK-101: NK cells from human placental CD34+ cells, altered to express cleavage-resistant CD16	Induction with Pembrolizumab, Trastuzumab and a Fluoropyrimidine/Platinum based Chemotherapy regimen	Locally Advanced Unresectable or Metastatic HER2+ GC or GEJC	Recruiting
NCT02839954 Phase I/II	anti-MUC1 CAR-NK cells	N/A	MUC1+ advanced refractory or relapsed solid tumors	Unknown